1Greenlee, RT, Hill-Harmon, MB, Murray, T, et al. (2001) Cancer statistics, 2001. CA Cancer J Clin 51, 15–36.
2Lu, C, Williams, AK, Chalasani, V, et al. (2011) Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? Expert Opin Biol Ther 11, 99–108.
3Sharma, S, Shin, JS, Grimshaw, M, et al. (2010) The senescence pathway in prostatic carcinogenesis. Pathology 42, 507–511.
4Thompson, IM, Tangen, CM, Klein, EA, et al. (2005) Phase III prostate cancer prevention trials: are the costs justified? J Clin Oncol 23, 8161–8164.
5Shukla, S & Gupta, S (2005) Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 53, 18–32.
6Reyes, FJ, Centelles, JJ, Lupianez, JA, et al. (2006) (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid, a new natural triterpene from Olea europaea, induces caspase dependent apoptosis selectively in colon adenocarcinoma cells. FEBS Lett 580, 6302–6310.
7Reyes-Zurita, FJ, Rufino-Palomares, EE, Lupianez, JA, et al. (2009) Maslinic acid, a natural triterpene from Olea europaea L. induces apoptosis in HT29 human colon-cancer cells via the mitochondrial apoptotic pathway. Cancer Lett 273, 44–54.
8Martin, R, Carvalho-Tavares, J, Ibeas, E, et al. (2007) Acidic triterpenes compromise growth and survival of astrocytoma cell lines by regulating reactive oxygen species accumulation. Cancer Res 67, 3741–3751.
9Bogenrieder, T & Herlyn, M (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22, 6524–6536.
10Bourboulia, D & Stetler-Stevenson, WG (2010) Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20, 161–168.
11Mekkawy, AH, Morris, DL & Pourgholami, MH (2009) Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol 5, 1487–1499.
12Yoon, SO, Park, SJ, Yun, CH, et al. (2003) Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36, 128–137.
13Kessenbrock, K, Plaks, V & Werb, Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52–67.
14Duffy, MJ, McGowan, PM & Gallagher, WM (2008) Cancer invasion and metastasis: changing views. J Pathol 214, 283–293.
15Patriarca, C, Macchi, RM, Marschner, AK, et al. (2011) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38, 68–75.
16van der Gun, BT, Melchers, LJ, Ruiters, MH, et al. (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31, 1913–1921.
17Folkman, J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29, 15–18.
18Fu, B, Xue, J, Li, Z, et al. (2007) Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. Mol Cancer Ther 6, 220–226.
19Lee, DH & Lee, YJ (2008) Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 105, 546–553.
20Semenza, GL (2006) Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets 10, 267–280.
21Zhong, H, De Marzo, AM, Laughner, E, et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59, 5830–5835.
22Maxwell, PH, Dachs, GU, Gleadle, JM, et al. (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 94, 8104–8109.
23Rankin, EB & Giaccia, AJ (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15, 678–685.
24Hicklin, DJ & Ellis, LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23, 1011–1027.
25Semenza, GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12, 853–859.
26Kwon, GT, Cho, HJ, Chung, WY, et al. (2009) Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J Nutr Biochem 20, 663–676.
27Kim, EJ, Kang, Y-H, Schaffer, BS, et al. (2002) Inhibition of Caco-2 cell proliferation by all-trans retinoic acid (tRA): role of insulin-like growth factor binding protein-6. J Cell Physiol 190, 92–100.
28Cho, HJ, Kim, WK, Kim, EJ, et al. (2003) Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. Am J Physiol Gastrointest Liver Physiol 284, G996–1005.
29Park, SY, Lim, SS, Kim, JK, et al. (2010) Hexane-ethanol extract of Glycyrrhiza uralensis containing licoricidin inhibits the metastatic capacity of DU145 human prostate cancer cells. Br J Nutr 104, 1272–1282.
30Kwon, GT, Jung, JI, Song, HR, et al. (2011) Piceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signaling. J Nutr Biochem 23, 228–238.
31Zhao, W, Wang, YS, Hui, YN, et al. (2008) Inhibition of proliferation, migration and tube formation of choroidal microvascular endothelial cells by targeting HIF-1alpha with short hairpin RNA-expressing plasmid DNA in human RPE cells in a coculture system. Graefes Arch Clin Exp Ophthalmol 246, 1413–1422.
32Maxwell, PH, Wiesener, MS, Chang, GW, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275.
33Chaffer, CL & Weinberg, RA (2011) A perspective on cancer cell metastasis. Science 331, 1559–1564.
34Woessner, JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5, 2145–2154.
35Christofori, G (2006) New signals from the invasive front. Nature 441, 444–450.
36Yao, H, Wang, H, Zhang, Z, et al. (2008) Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer 123, 1255–1261.
37Li, C, Yang, Z, Zhai, C, et al. (2010) Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappaB signaling pathway. Mol Cancer 9, 73.
38Semenza, GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8, S62–S67.
39Zhong, H, Chiles, K, Feldser, D, et al. (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60, 1541–1545.
40Dimova, EY, Michiels, C & Kietzmann, T (2009) Kinases as upstream regulators of the HIF system: their emerging potential as anti-cancer drug targets. Curr Pharm Des 15, 3867–3877.
41Blancher, C, Moore, JW, Robertson, N, et al. (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61, 7349–7355.
42Jiang, BH, Jiang, G, Zheng, JZ, et al. (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12, 363–369.
43Liu, LZ, Li, C, Chen, Q, et al. (2011) MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 6, e19139.
44Allouche, Y, Jimenez, A, Uceda, M, et al. (2009) Triterpenic content and chemometric analysis of virgin olive oils from forty olive cultivars. J Agric Food Chem 57, 3604–3610.
45Perez-Camino, MC & Cert, A (1999) Quantitative determination of hydroxy pentacyclic triterpene acids in vegetable oils. J Agric Food Chem 47, 1558–1562.
46Fernandez-Navarro, M, Peragon, J, Esteban, FJ, et al. (2010) Maslinic acid: a component of olive oil on growth and protein-turnover rates. In Olives and Olive Oil in Health and Disease Prevention, pp. 1415–1421 [Preedy, V and Watson, RR, editors]. Oxford: Academic Press.
47Vissers, MN, Zock, PL & Katan, MB (2004) Bioavailability and antioxidant effects of olive oil phenols in humans: a review. Eur J Clin Nutr 58, 955–965.